Corona RemediesQ1 FY27
Corona Remedies Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹2,100P/E: 61.9Market Cap: ₹13.1K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →CORONA Remedies targets 15% organic revenue growth for FY27, with an additional 25% growth expected from inorganic opportunities, totaling about 17% revenue growth overall.
- →The company aims to sustain double-digit industry growth, anticipating Indian Pharmaceutical Market (IPM) growth around 9%-11% annually.
- →Volume growth significantly outpaces the IPM, with 6.3% volume growth versus 1.3% for the IPM in MAT June 2026 (approx. 5x IPM).
- →Price-led growth and new product introductions also contribute, with prices growing at 8.7% versus IPM’s 5.6%, and new product introductions at 3.4% versus IPM’s 2.9%.
- →Strong ramp-up expected in IVF business over next 2-3 quarters as the MR taskforce scales efforts.
- →Export growth anticipated from new EU GMP hormonal plant, with dossiers expected ready by late 2026 and market entry soon after.
- →Operating leverage and marketing scale are expected to support sustainable revenue and volume growth over the medium term.
Margin guidance
Category 3- →CORONA Remedies targets a **15% organic revenue growth** and **20% PAT growth** for FY27 and near-term future.
- →The company expects to maintain or exceed this growth, supported by a strong brand portfolio and robust product pipeline.
- →Inorganic growth is guided at **25%**, stemming from recent acquisitions like Wokadine; this will be incremental to the organic growth.
- →Operating leverage is anticipated to improve margins over the next 2-3 years, aided by controlled medical representative additions and expected reduction in under-recoveries from the new hormonal plant.
- →The hormonal facility ramp-up, expected around Nov-Dec 2026, should support export growth and overall profitability.
- →EPS growth is aligned with PAT growth guidance of around 20%, reflecting sustained profit expansion.
3 more insights locked — sign up free to unlock
Fundraise plans
- →The transcript from the earnings call on August 03, 2026, does not mention any current or planned fundraising through debt or equity.
- →There is no explicit discussion about raising capital via new debt or equity in the provided pages.
- →The focus is primarily on organic growth, capacity expansion (such as the new hormonal plant), and brand acquisitions funded through internal means.
- →Capital expenditure mentioned, e.g., INR130 crores for the new hormonal facility, appears to be internally funded or from existing resources.
- →No specific guidance or plans for fundraising through new debt or equity are disclosed in these sections.
Order book
The transcript and document provided do not contain specific information regarding the current or expected order book or pending orders for CORONA Remedies Limited as of Q1 FY27. The discussion primarily focuses on financial performance, revenue growth, segmental performance, new product launches, operational updates, and expansion plans. There is no mention of order book status or pending orders in the earnings call transcript or related communications on page 18 or the rest of the document.
If you need detailed order book information, it is recommended to contact the company directly through their Investor Relations partner SGA or refer to official filings and investor presentations on their website.
Capex plans
Yes- →Corona Remedies Limited has recently commissioned a new EU GMP approved hormonal manufacturing plant with a capex of INR 130 crores.
- →The hormonal plant started operations on June 30, 2026, and is expected to have an asset turnover of less than 1x in FY27, gradually increasing to 2-3x over the next three years.
- →The company is in the final stages of preparing dossiers for this plant to enable international market entry, targeting FY28-29 for international scale-up.
- →Additional capital investments related to brand acquisitions include the Wokadine brand (acquired for INR 97 crores plus GST), amortized over 10 years, and a Bayer brand acquired for INR 7 crores.
- →No specific mention of new capex beyond the hormonal plant was highlighted in the current period, but the company plans ongoing investment in expanding manufacturing and market penetration.
How does Corona Remedies rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Corona Remedies
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Corona Remedies rank in Pharmaceuticals & Biotechnology?
Compare Corona Remedies against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.